NSTE ACS Routine Versus Selective Invasive Strategy Decision Tool

Clinical calculation support · Verify results before clinical use

Clinical assessment

Enter the GRACE score and select the findings that apply to the patient.

NSTE-ACS
Decision support
Enter the score calculated with a validated GRACE tool. This decision aid does not calculate GRACE itself.
Cardiac troponin elevated Use the assay-specific reference limit and serial results; interpret in the clinical context.
Ongoing dynamic ST-segment changes New or ongoing dynamic ischemic ECG changes.
Refractory or recurrent ischemia despite medical therapy Ongoing/recurrent ischemic symptoms despite appropriate treatment.
Hemodynamic or electrical instability For example, shock, serious sustained ventricular arrhythmia, or other instability.
Acute heart failure or pulmonary edema Acute/worsening heart failure, including pulmonary edema or new/worsening ischemic mitral regurgitation.
Clinical likelihood of true NSTE-ACS Select Yes when the overall clinical assessment supports NSTE-ACS rather than an alternative diagnosis.
Reset

How to interpret this decision aid

This tool supports, but does not replace, clinical assessment in suspected or established non-ST-segment elevation acute coronary syndrome (NSTE-ACS). It combines the entered GRACE score with selected clinical features to suggest an invasive strategy and timing.

Key decision principles

  • Immediate invasive assessment: refractory ischemia or hemodynamic/electrical instability requires urgent assessment; acute heart failure/pulmonary edema in the setting of NSTE-ACS is also a very-high-risk feature.
  • High risk: GRACE score >140 or ongoing dynamic ST-segment changes supports an early invasive approach; angiography within 24 hours is reasonable when clinically appropriate.
  • Intermediate risk: patients with established NSTE-ACS who are appropriate candidates for revascularization should generally undergo invasive assessment during hospitalization.
  • Low risk: either routine invasive assessment or selective invasive assessment with noninvasive risk stratification may be appropriate. Reassess if symptoms recur or new high-risk findings emerge.

Important limitations

The tool uses simplified categories and is not a validated risk score. It does not calculate GRACE, adjudicate myocardial infarction, or account for all contraindications, frailty, renal function, bleeding risk, coronary anatomy, patient preference, or local service capability. A troponin elevation alone does not automatically establish the need for angiography within 24 hours; interpret serial values and the clinical context.

References

Rao SV, O'Donoghue ML, Ruel M, et al.2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2025.doi:10.1016/j.jacc.2024.11.009
Byrne RA, Rossello X, Coughlan JJ, et al.2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–3826.doi:10.1093/eurheartj/ehad191
Clinical disclaimer: For use by qualified healthcare professionals as decision support. This tool is not intended for self-diagnosis and must not delay emergency care, transfer, or indicated coronary angiography. Final decisions require bedside assessment and current local protocols.